Quoin Pharmaceuticals (QNRX) announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting firm.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNRX:
- Quoin Pharmaceuticals releases fourth episode of NETHERTON NOW series
- Quoin Pharmaceuticals Reports Q2 2025 Financial Results
- Quoin Pharmaceuticals reports Q2 EPS ($6.28) vs ($13.68) last year
- Buy Rating for Quoin Pharmaceuticals: Promising Developments in Netherton Syndrome Treatment and Strategic Regulatory Advantages
- Quoin Pharmaceuticals provides update on its development product portfolio